GSK’s continuingcommitment to immunologyGSK is a science-led global healthcarecompany focused on driving scientificinnovation to further the development ofmedicines for immune-mediated diseases,such as lupus and rheumatoid arthritis.
Our world-leading scientists
are focused on the biology ofthe immune system with the aimto develop medicines that havethe potential to alter the courseof inflammatory disease.
Our goal – now and in the future –is to help people live their best day,every day.
Thank you and hopeto see you in personnext year at EULAR
2021 in Paris!
©2020 GSK group of companies. All rights reserved.
PM-GBL-LPU-ADVT-200001 Date of preparation: July 2020
Adverse events should be reported. Reporting forms andinformation can be found at www.mhra.gov.uk/yellowcard orsearch for MHRA Yellowcard in the Google Play or Apple Appstore. For Germany, adverse events should be reported toPaul-Ehrlich-Institut: www.pei.de or on +49 6103 77 0. Adverseevents should also be reported to GlaxoSmithKline on +44 800221 441 or, for Germany, to https://de.gsk.com, or on +49 800122 33 55. If you are professionally active in a country other thanGermany, adverse events should be reported to the appropriatehealth authority in your country.
Visit our GSK Congress pageto find more details about ourcommitment to immunology